⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Plus Therapeutics, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Plus Therapeutics, Inc.
↗Houston, Texas, USA
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of targeted radiotherapeutics for patients with rare and difficult-to-treat cancers, particularly those affecting the central nervous system (CNS). The company utilizes a hybrid virtual drug development model to enhance capital efficiency and accelerate product development.
In addition to its therapeutic pipeline, the company operates a wholly owned subsidiary, CNSide Diagnostics, LLC, which commercializes the CNSide® cerebrospinal fluid (CSF) assay platform. This diagnostic tool is designed to identify and characterize tumor cells that have metastasized to the CNS in patients with carcinomas and melanomas, providing critical information for patient management.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$0M-$10M
Founded:1996
Ownership:public
Status:operating
FUNDING
Stage:Public
STOCK
Exchange:NASDAQ
Ticker:PSTV
Market Cap:$0.04B
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Radiopharmaceuticals
Active Trials:3
Trial Phases:Phase 1: 2 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:CNSide Diagnostics, LLC
Key Partnerships:SpectronRx (Manufacturing), Radiomedix (Manufacturing), Telix Pharmaceuticals (Isotope supply)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Marc Hedrick - President and CEO
Andrew Sims - VP and CFO
Eric J. Daniels - Chief Development Officer
Scientific Founders:Ralph E. Holmes, Christopher J. Calhoun
Board Members:Richard Hawkins, Marc Hedrick, Ron Andrews, Howard Clowes, An van Es-Johansson, Kyle Guse
LINKS
Website:plustherapeutics.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Plus Therapeutics, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.